Recent Finacing
Recent Raise
Cyteir Therapeutics develops small-molecule RAD51 inhibitors and synthetic-lethality therapies targeting DNA repair for oncology (CYT-0851 in Phase 1/2) and companion diagnostics, with preclinical autoimmune programs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Cyteir Therapeutics.
